24 results
8-K
EX-99.1
ARVN
Arvinas Inc
7 May 24
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:02am
trial of vepdegestrant plus atirmociclib, Pfizer’s novel CDK4 inhibitor.
ARV-766
Following US antitrust regulatory review, currently expected
8-K
EX-99.1
ARVN
Arvinas Inc
11 Apr 24
Entry into a Material Definitive Agreement
7:03am
consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
8-K
ARVN
Arvinas Inc
11 Apr 24
Entry into a Material Definitive Agreement
7:03am
, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The License Agreement
8-K
apwl rprxf3
13 Sep 21
Other Events
4:09pm
424B5
r3lfbspmm9hp
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
cxof70t04cpl
5 Aug 21
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
p6k3db
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-99.1
0yk061 wy17qcc
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
nf3az8fz7yw0p mvfq
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
424B3
es6yy77x7 y8vgv2v7
11 Oct 19
Prospectus supplement
7:44am
S-3
ku36x5
1 Oct 19
Shelf registration
6:37pm